Journal
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY
Volume 48, Issue 3, Pages 292-294Publisher
SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnmt.119.237354
Keywords
sinonasal neuroendocrine carcinoma; Ga-68-DOTATATE PET/CT; F-18-FDG PET/CT; Lu-177-DOTATATE; peptide receptor radionuclide therapy; dual-tracer PET/CT
Ask authors/readers for more resources
Sinonasal neuroendocrine carcinomas (SNCs), in contrast to neuroendocrine carcinomas at other sites, are notorious for their recurrent and locally aggressive nature. The clinical concern is primarily due to their complex anatomy and close proximity to vital structures, compounded by lack of proper understanding of pathogenesis, no definitive classification or staging system, and no established treatment guidelines. We present the promise of combined treatment with Lu-177-DOTATATE-based peptide receptor radionuclide therapy (PRRT) and platinum-based chemotherapy in a patient with high-grade, recurrent, and metastatic SNC (that demonstrated high uptake on both Ga-68-DOTATATE and F-18-FDG PET/CT), which showed a significant partial response. The case report highlights the feasibility and effectiveness of applying a combined protocol of Lu-177-DOTATATE and platinum-based chemotherapy in the management of high-grade, recurrent, metastatic SNC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available